Dianthus Therapeutics, Inc. /DE/ Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value
Dianthus Therapeutics, Inc. /DE/ (DNTH) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value of $181.22 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue · last filed 2026-08-04
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value $181.22M.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value $132.93M.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value $57.82M.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value $55.74M.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value |
|---|---|
| 2026-06-30 | $181.22M 10-Q · filed 2026-08-04 |
| 2026-03-31 | $132.93M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $57.82M 10-K · filed 2026-03-09 |
| 2025-09-30 | $55.74M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $11.68M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $10.48M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $14.40M 10-K · filed 2025-03-11 |
| 2024-09-30 | $19.66M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $15.43M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $15.60M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $1.51M 10-K · filed 2024-03-21 |
| 2023-09-30 | $2.95M 10-Q · filed 2023-11-09 |
| 2022-12-31 | $229.00K 8-K · filed 2023-12-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |